Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin add-on therapy in hospitalized COVID-19 patients
IRCT20230722058883N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Disease severity, Progression to severe complications and 1 more. Started Apr 2020; status: completed.
02
Drugs
rosuvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20230722058883N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230722058883N2.